FDA approves over-the-counter naloxone nasal spray from nonprofit to combat opioid overdoses
- The FDA approved the over-the-counter sale of RiVive, a naloxone nasal spray, to treat opioid overdoses.
- RiVive, made by nonprofit Harm Reduction Therapeutics, is the second OTC naloxone product approved by the FDA.
- It will be available in early 2024, primarily to harm reduction groups and governments at low or no cost.
- At least 200,000 free doses of RiVive will be provided by the manufacturer.
- Naloxone quickly reverses opioid overdoses and increased access is seen as an important public health tool.
Washington Examiner 
The Hill 
UPI 
Reuters 
